Sight Sciences (SGHT) Investor presentation summary

Q3 performance and FY26 outlook

• Q3 2026 revenue $24.9M, up 25% YoY; third consecutive quarter of double-digit growth, with IDE scaling rapidly.

• YTD revenue $68.0M, up 19%; adjusted OpEx $67.5M, down 2%, and 99% of revenue vs. 121% in prior-year period.

• YTD glaucoma revenue $60.1M, up 7%; interventional dry-eye revenue $7.9M vs. $0.9M in the prior year.

• Cash usage improved 74% YoY.

• FY26 guidance: revenue $92M-$93M, up 19%-20% YoY; adjusted OpEx $92M-$94M, up 5%-7%.

Interventional dry eye

• ~7-8M U.S. patients have moderate-to-severe MGD-associated dry eye, the targeted population in the SAHARA trial.

• TearCare is indicated to improve meibomian gland function; its procedure combines wearable SmartLids, controlled thermal therapy and manual gland expression.

• In SAHARA, TearCare was superior to Restasis in TBUT at 6 months and non-inferior in OSDI; prior Restasis patients improved after crossover to TearCare.

• At 24 months, mean signs and symptoms remained significantly better than baseline; 66% treated at baseline and Month 5 needed no further treatment under trial retreatment criteria.

• Commercial plan targets ~6,500 physicians and an installed base of over 80,000 SmartLids sold; IDE procedures grew following Oct. 2025 MAC fee schedules.

Interventional glaucoma

• More than 4M U.S. patients are diagnosed with glaucoma, which is predominantly managed with daily eye drops; adherence is often poor.

• OMNI treats the conventional outflow pathway, with up to 360-degree treatment of its three resistance areas; over 430K procedures have been performed.

• OMNI is implant-free MIGS with an FDA indication for standalone or cataract-combination procedures in adults with POAG across disease severity.

• GEMINI 2 combination-cataract data showed IOP of 16.3 mmHg at Month 36 vs. 23.1 mmHg at baseline, and 0.4 medications vs. 1.63 at baseline.

• Standalone MIGS addresses an unmet need: ~85% of POAG eyes are standalone candidates, while standalone procedures represent ~10% of MIGS procedures.